Harnessing drug resistance: Using ABC transporter proteins to target cancer cells

Biochemical Pharmacology

Volumn 74, Issue 12, 2007, Pages 1677-1685

  Leitner, Heather M ^a   Kachadourian, Remy ^b   Day, Brian J ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Chemotherapy; Flavonoids; Glutathione; Multidrug resistance proteins; Oxidative stress

Indexed keywords

2 BROMOMETHAMPHETAMINE; ABC TRANSPORTER; ANTIRETROVIRUS AGENT; BUTHIONINE SULFOXIMINE; COLCHICINE; CYCLIC NUCLEOTIDE; CYCLOSPORIN A; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLUTATHIONE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROSTAGLANDIN DERIVATIVE; PSC 8233; PURINE DERIVATIVE; RHODAMINE; SAQUINAVIR; SULFINPYRAZONE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL DIVISION; CLINICAL TRIAL; DNA SYNTHESIS; HUMAN; HUMAN CELL; LIVER TOXICITY; NAUSEA; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; VOMITING; XENOBIOTIC METABOLISM;

EID: 36048948042     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.05.014     Document Type: Note

References (75)

1. Wilson D.B. Cellular transport mechanisms. Annu Rev Biochem 47 (1978) 933-965
2. Berger E.A., and Heppel L.A. Different mechanisms of energy coupling for the shock-sensitive and shock-resistant amino acid permeases of Escherichia coli. J Biol Chem 249 (1974) 7747-7755
3. Gilson E., Higgins C.F., Hofnung M., Ferro-Luzzi Ames G., and Nikaido H. Extensive homology between membrane-associated components of histidine and maltose transport systems of Salmonella typhimurium and Escherichia coli. J Biol Chem 257 (1982) 9915-9918
4. Higgins C.F., Haag P.D., Nikaido K., Ardeshir F., Garcia G., and Ames G.F. Complete nucleotide sequence and identification of membrane components of the histidine transport operon of S. typhimurium. Nature 298 (1982) 723-727
5. Walker J.E., Saraste M., Runswick M.J., and Gay N.J. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1 (1982) 945-951
6. Hobson A.C., Weatherwax R., and Ames G.F. ATP-binding sites in the membrane components of histidine permease, a periplasmic transport system. Proc Natl Acad Sci USA 81 (1984) 7333-7337
7. Higgins C.F., Hiles I.D., Whalley K., and Jamieson D.J. Nucleotide binding by membrane components of bacterial periplasmic binding protein-dependent transport systems. EMBO J 4 (1985) 1033-1039
8. Higgins C.F., Hiles I.D., Salmond G.P., Gill D.R., Downie J.A., Evans I.J., et al. A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature 323 (1986) 448-450
9. Bishop L., Agbayani Jr. R., Ambudkar S.V., Maloney P.C., and Ames G.F. Reconstitution of a bacterial periplasmic permease in proteoliposomes and demonstration of ATP hydrolysis concomitant with transport. Proc Natl Acad Sci USA 86 (1989) 6953-6957
10. Mimmack M.L., Gallagher M.P., Pearce S.R., Hyde S.C., Booth I.R., and Higgins C.F. Energy coupling to periplasmic binding protein-dependent transport systems: stoichiometry of ATP hydrolysis during transport in vivo. Proc Natl Acad Sci USA 86 (1989) 8257-8261
11. Holland I.B. ABC proteins: from bacteria to man (2003), Boston, Mass.: Academic Press, Amsterdam
12. Dean M., and Allikmets R. Evolution of ATP-binding cassette transporter genes. Curr Opin Genet Dev 5 (1995) 779-785
13. Allikmets R., Gerrard B., Hutchinson A., and Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet 5 (1996) 1649-1655
14. Gros P., Croop J., and Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 47 (1986) 371-380
15. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., and Gottesman M.M.E.-A. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47 (1986) 381-389
16. Dean M. The human ATP-binding cassette (ABC) transporter superfamily (2002), National Center for Biotechnology Information
17. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5 (2006) 219-234
18. Boumendjel A., Baubichon-Cortay H., Trompier D., Perrotton T., and Di Pietro A. Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents. Med Res Rev 25 (2005) 453-472
19. Scheffer G.L., Pijnenborg A.C., Smit E.F., Muller M., Postma D.S., and Timens W.E.-A. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 55 (2002) 332-339
20. Sandusky G.E., Mintze K.S., Pratt S.E., and Dantzig A.H. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41 (2002) 65-74
21. Gutmann H., Hruz P., Zimmermann C., Beglinger C., and Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol 70 (2005) 695-699
22. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61 (2001) 3458-3464
23. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijk M.J., Juijn J.A., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57 (1997) 3537-3547
24. Langmann T., Mauerer R., Zahn A., Moehle C., Probst M., Stremmel W., et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 49 (2003) 230-238
25. Nishimura M., and Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20 (2005) 452-477
26. Wright S.R., Boag A.H., Valdimarsson G., Hipfner D.R., Campling B.G., Cole S.P., et al. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res 4 (1998) 2279-2289
27. Scheffer G.L., Kool M., Heijn M., de Haas M., Pijnenborg A.C., Wijnholds J., et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60 (2000) 5269-5277
28. Zhang W., Shannon W.D., Duncan J., Scheffer G.L., Scheper R.J., and McLeod H.L. Expression of drug pathway proteins is independent of tumour type. J Pathol 209 (2006) 213-219
29. van der Deen M., de Vries E.G., Timens W., Scheper R.J., Timmer-Bosscha H., and Postma D.S. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 6 (2005) 59
30. Szakacs G., Annereau J.P., Lababidi S., Shankavaram U., Arciello A., et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6 (2004) 129-137
31. Kruh G.D. Introduction to resistance to anticancer agents. Oncogene 22 (2003) 7262-7264
32. Zhou D.C., Zittoun R., and Marie J.P. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 9 (1995) 1661-1666
33. Meister A. New aspects of glutathione biochemistry and transport: selective alteration of glutathione metabolism. Fed Proc 43 (1984) 3031-3042
34. Zelcer N., Saeki T., Reid G., Beijnen J.H., and Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276 (2001) 46400-46407
35. Lorico A., Rappa G., Finch R.A., Yang D., Flavell R.A., and Sartorelli A.C. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 57 (1997) 5238-5242
36. Day B.J., van Heeckeren A.M., Min E., and Velsor L.W. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary pseudomonas infection. Infect Immun 72 (2004) 2045-2051
37. Ballatori N., Hammond C.L., Cunningham J.B., Krance S.M., and Marchan R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol Appl Pharmacol 204 (2005) 238-255
38. Hong H., Lu Y., Ji Z.N., and Liu G.Q. Up-regulation of P-glycoprotein expression by glutathione depletion-induced oxidative stress in rat brain microvessel endothelial cells. J Neurochem 98 (2006) 1465-1473
39. Loe D.W., Oleschuk C.J., Deeley R.G., and Cole S.P. Structure-activity studies of verapamil analogs that modulate transport of leukotriene C(4) and reduced glutathione by multidrug resistance protein MRP1. Biochem Biophys Res Commun 275 (2000) 795-803
40. Leslie E.M., Deeley R.G., and Cole S.P. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab Dispos 31 (2003) 11-15
41. Sabzevari O., Galati G., Moridani M.Y., Siraki A., and O'Brien P.J. Molecular cytotoxic mechanisms of anticancer hydroxychalcones. Chem Biol Interact 148 (2004) 57-67
42. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol Pharmacol 65 (2004) 1375-1385
43. Nicco C., Laurent A., Chereau C., Weill B., and Batteux F. Differential modulation of normal and tumor cell proliferation by reactive oxygen species. Biomed Pharmacother 59 (2005) 169-174
44. Armstrong J.S. Mitochondria: a target for cancer therapy. Br J Pharmacol 147 (2006) 239-248
45. Kachadourian R., Leitner H.M., and Day B.J. Selected flavonoids potentiate the toxicity of cisplatin in human lung adenocarcinoma cells: a role for glutathione depletion. Int J Oncol 31 (2007) 161-168
46. Allen R.G., and Balin A.K. Effects of oxygen on the antioxidant responses of normal and transformed cells. Exp Cell Res 289 (2003) 307-316
47. Schirmer R., Drauth-Siegel R., and Schulz G.E. Glutathione reductase. In: Dolphin D., Poulson R., and Avramovic O. (Eds). Coenzymes and cofactors (1989), Wiley, New York 553-596
48. Townsend D.M., and Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22 (2003) 7369-7375
49. Batist G., Schecter R.L., and Alaoui-Jamali M.A. The glutathione system and drug resistance. In: Shilsky R., Milano G., and Ratain M. (Eds). Principles of antineoplastic drug development and pharmacology (1996), Marcel Dekker Inc., New York 503-521
50. Nguyen P., Awwad R.T., Smart D.D., Spitz D.R., and Gius D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett 236 (2006) 164-174
51. Patt H.M., Tyree E.B., Straube R.L., and Smith D.E. Cysteine protection against X irradiation. Science, New Series 110 (1949) 213-214
52. Karnofsky D.A. Differences between cancers in terms of therapeutic responses. Cancer Res 16 (1956) 684-697
53. Law L.W. Differences between cancers in terms of evolution of drug resistance. Cancer Res 16 (1956) 698-716
54. Ball C.R., Connors T.A., Double J.A., Ujhazy V., and Whisson M.E. Comparison of nitrogen-mustard sensitive and -resistant Yoshida sarcomas. Int J Cancer 1 (1966) 319-327
55. Suzukake K., Petro B.J., and Vistica D.T. Reduction in glutathione content of L-PAM resistant L1210 Cells confers drug sensitivity. Biochem Pharmacol 31 (1982) 121-124
56. Griffith O.W., and Meister A. Differential inhibition of glutamine and gamma-glutamylcysteine synthetases by alpha-alkyl analogs of methionine sulfoximine that induce convulsions. J Biol Chem 253 (1978) 2333-2338
57. Griffith O.W., Anderson M.E., and Meister A. Inhibition of glutathione biosynthesis by prothionine sulfoximine (S-n-propyl homocysteine sulfoximine), a selective inhibitor of gamma-glutamylcysteine synthetase. J Biol Chem 254 (1979) 1205-1210
58. Griffith O.W., and Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254 (1979) 7558-7560
59. Andringa K.K., Coleman M.C., Aykin-Burns N., Hitchler M.J., Walsh S.A., Domann F.E., et al. Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-d-glucose. Cancer Res 66 (2006) 1605-1610
60. Rudin C.M., Yang Z., Schumaker L.M., VanderWeele D.J., Newkirk K., Egorin M.J., et al. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63 (2003) 312-318
61. Leung S.W., Mitchell J.B., al-Nabulsi I., Friedman N., Newsome J., Belldegrun A., et al. Effect of l-buthionine sulfoximine on the radiation response of human renal carcinoma cell lines. Cancer 71 (1993) 2276-2285
62. Armstrong J.S., and Jones D.P. Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in Bcl-2 overexpressing HL60 cells. FASEB J 16 (2002) 1263-1265
63. Ozols R.F., Louie K.G., Plowman J., Behrens B.C., Fine R.L., Dykes D., et al. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 36 (1987) 147-153
64. Lee F.Y., Allalunis-Turner M.J., and Siemann D.W. Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine. Br J Cancer 56 (1987) 33-38
65. Bailey H.H., Mulcahy R.T., Tutsch K.D., Arzoomanian R.Z., Alberti D., Tombes M.B., et al. Phase I clinical trial of intravenous l-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 12 (1994) 194-205
66. Gallo J.M., Brennan J., Hamilton T.C., Halbherr T., Laub P.B., Ozols R.F., et al. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res 55 (1995) 4507-4511
67. O'Dwyer P.J., Hamilton T.C., LaCreta F.P., Gallo J.M., Kilpatrick D., Halbherr T., et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 14 (1996) 249-256
68. Bailey H.H., Ripple G., Tutsch K.D., Arzoomanian R.Z., Alberti D., Feierabend C., et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 89 (1997) 1789-1796
69. Grech K.V., Davey R.A., and Davey M.W. The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells. Biochem Pharmacol 55 (1998) 1283-1289
70. Benlloch M., Ortega A., Ferrer P., Segarra R., Obrador E., Asensi M., et al. Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J Biol Chem 280 (2005) 6950-6959
71. Trompier D., Chang X.B., Barattin R., du Moulinet D'Hardemare A., Di Pietro A., and Baubichon-Cortay H. Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 64 (2004) 4950-4956
72. Laberge R.M., Karwatsky J., Lincoln M.C., Leimanis M.L., and Georges E. Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress. Biochem Pharmacol 73 (2007) 1727-1737
73. Kachadourian R., and Day B.J. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic Biol Med 41 (2006) 65-76
74. Vollrath V., Wielandt A., Iruretagoyena M., and Chianale J. Role of Nrf2 in the regulation of Mrp2 (ABCC2) gene. Biochem J 395 (2006) 599-609
75. Scotto K. Transcriptional regulation of ABC drug transporters. Oncogene 22 (2003) 7496-7511